AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05303649 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Noninvasive transcranial brain stimulation: excitatory iTBS
Description: 600 pulses (3 pulses at 50 Hz given every 200 milliseconds in 2-second trains at 10-second intervals, delivered at 80% of active motor threshold) generated by Magstim Super Rapid2 stimulator equipped with a figure-of-eight coil applied over BA 45 Device: Magstim Co., Wales, UK.
Study NCT05303649 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Noninvasive transcranial brain stimulation: inhibitory cTBS
Description: 600 pulses (3 pulses at 50 Hz, repeated at 5 Hz, delivered at 80% of active motor threshold) generated by Magstim Super Rapid2 stimulator equipped with a figure-of-eight coil applied over BA 45 homologue Device: Magstim Co., Wales, UK.
Study NCT05303649 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individual speech-language therapy (SLT)
Description: 45 minutes training tailored to every patient's deficits, abilities and needs. Exercises used during each therapeutic session include: expressions tasks (naming and sentence building), complex utterances comprehension tasks, reading and writing exercises. Training is administered using paper-and-pencil tasks and computerized aphasia therapy program AfaSystem (Harpo sp.zoo, Poznań, Poland).
Study NCT05303649 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Individual speech-language therapy (SLT)
Description: 45 minutes training tailored to every patient's deficits, abilities and needs. Exercises used during each therapeutic session include: expressions tasks (naming and sentence building), complex utterances comprehension tasks, reading and writing exercises. Training is administered using paper-and-pencil tasks and computerized aphasia therapy program AfaSystem (Harpo sp.zoo, Poznań, Poland).
Study NCT05303649 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham TBS simulating left hemispheric iTBS
Description: Sham TMS coil positioned exactly like an active TMS coil resulting in a very good approximation of the auditory effects Device: Magstim Co., Wales, UK.
Study NCT03864094 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ephedrine
Description: 0,1 mg/kg
Study NCT03864094 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenylephrine
Description: 1 microg/kg
Study NCT03864094 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norepinephrine
Description: 0,1 microg/kg
Study NCT03864094 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Sodium chloride
Description: 0,1 ml/kg
Study NCT03864094 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: 2 mg/kg
Study NCT03864094 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Propofol
Description: 2 mg/kg
Study NCT03864094 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: 1,7 microg/kg
Study NCT03864094 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Remifentanil
Description: 1,7 microg/kg
Study NCT04989517 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AT193
Description: Topical
Study NCT04989517 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AT193
Description: Topical
Study NCT05496426 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: KL130008/Placebo
Description: Drug: KL130008 Drug: Placebo
Study NCT06207175 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nonavalent HPV study vaccine
Description: A 3-dose regimen administered at months 0, 2 and 6.
Study NCT06207175 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: GARDASIL® 9
Description: A 3-dose regimen administered at months 0, 2 and 6.
Study NCT05269134 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bacteriophage
Description: Phage Therapy
Study NCT05269134 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT06302205 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical activity
Description: The home-based training intervention consists of two phases of each three months in duration. It consists of three weekly aerobic training sessions on the one hand, and two weekly training sessions focused on strength, balance, and flexibility on the other hand.
Study NCT06302205 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham intervention
Description: 2 times a week, flexibility and balance training
Study NCT05181917 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: STUDIA app
Description: STUDIA application has two functions, an insulin bolus calculator that estimates the amount of insulin according to the amount of carbohydrates that the patients compute, the insulin sensitivity factor, and the insulin/carbohydrate ratio provide by their treating physician. The application has a graphical interface that shows a glucose curve four hours after the meal. . This graph is built using the estimations made by an MSBF based on some characteristics of the patient previously recorded in the same application, the amount of carbohydrates entered to calculate the insulin bolus, and an estimate of the fat and protein content of the meal.
Study NCT05181917 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: STUDIA app
Description: STUDIA application has two functions, an insulin bolus calculator that estimates the amount of insulin according to the amount of carbohydrates that the patients compute, the insulin sensitivity factor, and the insulin/carbohydrate ratio provide by their treating physician. The application has a graphical interface that shows a glucose curve four hours after the meal. . This graph is built using the estimations made by an MSBF based on some characteristics of the patient previously recorded in the same application, the amount of carbohydrates entered to calculate the insulin bolus, and an estimate of the fat and protein content of the meal.
Study NCT06094777 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HY-0102
Description: Multiple dose cohorts, 60 minute IV infusion, every two weeks, 28 days as a cycle
Study NCT00013039 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Computer reminders
Study NCT04003506 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine
Description: LIA with ACB will be given using 10ml of 1.33% liposomal bupivacaine + 10ml 0.5% standard bupivacaine
Study NCT04003506 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine Injection
Description: LIA with ACB will be given using 20ml 0.5% standard bupivacaine
Study NCT05299827 — intervention group
Intervention type: OTHER
Intervention: The same evaluation methods were used for both groups.
Description: No treatment applied to participants and same evaluation methods used in both groups. Trunk muscle strength, muscle endurance, posture, flexibility and pelvic floor muscle activity of participants was evaluated with stabilizer pressurized biofeedback unit, sit-ups and modified push-ups test; trunk flexors endurance test and Modified Biering Sorensen Test; Posture Screen Mobile And Foot Posture Index; sit-reach-test and Beighton Score; and NeuroTrac-Myoplus4Pro,
Study NCT04743414 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTP-543
Description: Itraconazole in solution dosage form
Study NCT06440590 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: suprapectineal quadrilateral buttress plating
Description: 15 cases will undergo anatomical supra-pectineal quadrilateral plate
Study NCT06440590 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Infra-pectineal plating
Description: 15 cases will undergo conventional manually contoured infra-pectineal plate
Study NCT04445116 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Action Video Game Treatment
Description: Endeavor™ is a digital, non-drug investigational treatment that is delivered through an action video game and is designed to target cognitive deficits in adolescence and young adults with pediatric onset MS.
Study NCT06037538 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: blood glucose measurement by subject
Description: blood glucose measurement by subject using finger tip capillary blood
Study NCT06012838 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cause classification of OHCA protocol
Description: training program with cause classification of OHCA protocol
Study NCT06037538 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: blood glucose measurement with reference
Description: blood glucose measurement with reference method using finger tip capillary blood
Study NCT05122754 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B/F/TAF
Description: Bictegravir/emtricitabine/tenofovir alafenamide once daily, 1 tablet at a time, with or without food for 48 weeks.
Study NCT05122754 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TDF-based triple ART regimen switching to B/F/TAF
Description: Tenofovir disoproxil fumarate was administered once daily, one tablet at a time, with or without food. After Week 24, control subjects were also switched to bictegravir/emtricitabine/tenofovir alafenamide once daily, one tablet at a time, with or without food for the later 24 weeks.
Study NCT05585411 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Left bundle branch area pacing
Description: LBBAP success is defined if ventricular lead is successfully placed at interventricular septum and RBB configuration observed during unipolar tip pacing.~LBB capture is defined if fulfilling criterion 1 and at least one in criteria 2.~1. RBBB configuration observed during unipolar tip pacing~2. One of the following should be met:~   1. Abrupt shortening of Stim-LVAT (stimulus to peak of the R wave in V6 \[LV activation time\]) of >10ms during increasing output~  2. Short and constant stim-LVAT and the shortest stim-LVAT \<75ms in non-LBBB and \<85ms in LBBB~  3. Programmed stimulation by pacing lead changes QRS morphology from nonselective LBB to LV septal capture~  4. LBB potential (LBB-V interval of 15 to 35ms)~  5. Transition from nonselective LBB capture to selective LBB capture at near threshold outputs~If criterion 1 is fulfilled but none in criteria 2 is met, the procedure is considered to be deep septal pacing (DSP).
Study NCT05585411 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Right ventricular pacing
Description: Right ventricular pacing is the traditional pacing modality for ventricular pacing. Implantation of a RV pacing lead (apex or septum of right ventricle) will be attempted using the standard-of-care technique first
Study NCT05078567 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 5% Natural Lactic Acid-enriched Cream
Description: The subjects were required to topically apply natural lactic acid-enriched cream twice daily in the morning and evening for the treatment duration of 12 weeks.
Study NCT05164952 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic Acid 4 MG
Description: (4 mg via 15-min infusion every 6 months) for 24 months
Study NCT05091801 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Description: Participants will have one week of increased chewing time (chew food until they reach an apple sauce consistency)
Study NCT04863287 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 2217LS
Description: Fully Human Monoclonal Antibody
Study NCT05719467 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Buscopan 20 MG/ML Injectable Solution
Description: 1 mL intravenously
Study NCT04863287 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Sodium Chloride (NaCl)
Description: Subcutaneous injection
Study NCT06570707 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brighter Bites
Description: Families will receive a distribution of fresh fruits and vegetables (FV) (\~20lbs., 50 servings/family/distribution) for \~16 weeks during the school year using primarily donated produce from local food banks. Nutrition education will be implemented for children using the evidence-based Coordinated Approach to Child Health (CATCH) program and for parents using bilingual nutrition handbooks and fun food experiences such as healthy FV recipe tastings for families during produce pick-up time will be conducted.
Study NCT05638386 — intervention group
Intervention type: PROCEDURE
Intervention: Bone plug
Description: The investigational treatment is the use of a bone plug in the two drill-holes in the tibia, made by two pins for securing the tibial array to the bone. The pins that are used for this, are 4.0mm wide. The bone plug that is used to fill the drill-holes of tibia, is obtained from the bone that is removed during the operation to make place for the new prosthesis. A piece as wide as the drill-hole is cut off the recessed bone and put into this hole. After this, the wound is closed using surgical staples.
Study NCT05221294 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modified Del Nido Versus Custodiol Cardioplegia
Description: Modified Del Nido Versus Custodiol Cardioplegia For Myocardial Protection In Cardiac Surgery
Study NCT05173272 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neoadjuvant Therapy
Description: Cisplatin 50 mg/m\^2 d1 q21+ Paclitaxel 175 mg/m\^2 d1 q21+serplulimab 300mg d1 q21
Study NCT05173272 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: CCRT
Description: weekly cisplatin for 4 or 5 weeks is administered concomitant with EBRT (45-50.4Gy) in 1.8-2 daily fractions and a 10-20 Gy boost to reach a total dose of 65 Gy when there was unresectable lymph nodes.
Study NCT05173272 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Brachytherapy
Description: The primary cervical tumor is the boosted, using image guided 3D brachytherapy or 2D brachytherapy, with an additional 30-40 Gy to HRCTV (3D brachytherapy) or to point A (2D brachytherapy), to achieve a total dose of 80 Gy for small-volume cervical tumors or 85 Gy for larger-volume cervical tumors.
Study NCT05186558 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: penpulimab, lenalidomide, Rituximab, Gemcitabine, Oxaliplatin
Description: Patients receive penpulimab+R2-GemOx two weeks for a cycle, detailed as follows:~Combination therapy Anti-PD-1 antibody (penpulimab): Fixed dose of 200 mg every 2 weeks, d0, intravenous drip (without pretreatment), for 6 cycles.~R2-GemOx: lenalidomide 10 mg，d1-7; Rituximab 375mg/m2, d0; Gemcitabine 1000mg, d1; Oxaliplatin 100mg/m2, d1; every 2 weeks for a cycle, 6 cycles as protocol specified.~Maintenance treatment:~Combination of two drugs:~* Anti-PD-1 antibody (penpulimab): Fixed dose of 200 mg every 2 weeks, d0, intravenous drip (without pretreatment), , for 6 months~* lenalidomide: 10 mg, po, for 18 months.
Study NCT04982965 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Active Cannabis
Description: 400 mg of vaporized and inhaled active cannabis (5.1%)
Study NCT04982965 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Cannabis
Description: 400 mg of vaporized and inhaled placebo cannabis (\<.1%)
Study NCT03789773 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Millimeter-Wave Holographic Imaging
Description: Undergo mm-wave holographic imaging
Study NCT04908189 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deucravacitinib
Description: Specified dose on specified days
Study NCT04908189 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Deucravacitinib
Description: Specified dose on specified days
Study NCT04908189 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Specified dose on specified days
Study NCT04908189 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Apremilast
Description: Specified dose on specified days
Study NCT05905328 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTO1681 10 μg
Description: Administered 3 times daily for 15 days (initial cohort).
Study NCT05905328 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTO1681 20 μg
Description: Administered 3 times daily for 15 days (successive cohort).
Study NCT05905328 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTO1681 30 μg
Description: Administered 3 times daily for 15 days (successive cohort).
Study NCT06438276 — intervention group
Intervention type: BEHAVIORAL
Intervention: Psychiatric outreach nurse service
Description: Mental health service provided by psychiatric outreach nurses for 12-16 year old students in secondary schools
Study NCT05914272 — intervention group
Intervention type: DRUG
Intervention: Osmotic drugs
Description: Patients had used osmotic drugs within 72 hours of admission.
Study NCT06457321 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Sequence in receiving the fabricated dentures made using the conventional and partial digital method
Description: Participants is not informed on the sequence they have been randomized hence they are not able to determine which denture is fabricated from which method. This would reduce bias when collecting the participants' responses in the satisfaction questionnaire during the review visits.
Study NCT05719467 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium bicarbonate
Description: 4 g orally
Study NCT05719467 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: 4g orally
Study NCT05719467 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 4g orally
Study NCT05719467 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nacl 0.9%
Description: 1 mL intravenously
Study NCT05719467 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nacl 0.9%
Description: 1 mL intravenously
Study NCT05783869 — intervention group
Intervention type: DEVICE
Intervention: Echocardiography
Description: echocardiographic study of both groups
Study NCT04848688 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxidectin 2 mg
Description: Monotherapy, oral administration, single-dose, fixed-dose, 4 tablets of 2 mg each to yield an 8 mg final dose.
Study NCT04848688 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivermectin 3 mg
Description: Monotherapy, oral administration, single-dose, weight dependent, The number of tablets will be adjusted according to the patients' weight to yield 200 ug/kg final dose.
Study NCT04848688 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Monotherapy, oral administration, single dose, matching number of tablets to either moxidectin or ivermectin
Study NCT05995769 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin
Description: Single dosing session followed by 5 MET weekly sessions starting 24hrs after dosing
Study NCT05995769 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Psilocybin
Description: Single dosing session followed by 5 MET weekly sessions starting 24hrs after dosing
Study NCT05554887 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thrust manipulation
Description: Participants will be positioned prone and the clinician will perform a high-speed, low-amplitude thrust into the most symptomatic segment of the thoracic spine. TM type, thrust direction, and number of thrusts will be at the clinician's discretion and will be based on the individualized assessment of the patient.
Study NCT05554887 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham thrust manipulation
Description: The same protocol will be applied as the push thoracic manipulation application, but no push will be applied.
Study NCT06306157 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose naltrexone
Description: While naltrexone is FDA-approved for treatment of alcohol or opioid addition, this study will be looking at how naltrexone, when dosed very low, may reduce the painful symptoms associated with CRPS. Naltrexone is not FDA-approved for pain management treatment of CRPS at this time, and therefore the study intervention is using the drug in an off-label manner.
Study NCT05930925 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [phenyl-14C]ARV-471
Description: Participants will receive a single dose of \[phenyl-14C\]ARV-471 by mouth
Study NCT05930925 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [oxoisoindolin-14C]ARV-471
Description: Participants will receive a single dose of \[oxoisoindolin-14C\]ARV-471 by mouth
Study NCT06306157 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo sugar capsules
Description: The external appearance of the capsules prepared by the pharmacy will be identical to the LDN capsules. The inactive capsule ingredients will be microcrystalline cellulose (MCC) and Magnesium stearate
Study NCT04798417 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic supplement
Description: Use of a probiotic sachet
Study NCT04798417 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Prebiotic supplement
Description: Prebiotic sachets
Study NCT04798417 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: Placebo comparator
Study NCT05415059 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Covatech Stoma bag material
Description: Strips of Covatech Stoma bag used to asses adhesion of 3M material to be used in LEAFix device
Study NCT05788328 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dabigatran etexilate (DE)
Description: Dabigatran etexilate (DE) as oral capsule
Study NCT05788328 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate (DE)
Description: Dabigatran etexilate (DE) as oral capsule
Study NCT05200442 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VS-6766/avutometinib
Description: An oral anti-cancer medication.